Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals has filed its first Drug Master File of Recombinant Human Albumin 20% with United States Food and Drug Administration (USFDA). This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process which is completely-Environment friendly, Consistent High-Quality product, Scalable to massive scales and is cost competitive. Recombinant Human Albumin 20% targets to fulfil growing demand of human serum albumin to deliver current and growing market demand.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
